PPD

MAY 11, 2023

However, due to the pharmacokinetic and pharmacodynamic physiological changes that come with age and the presence of multi-morbidity, this type of extrapolation is not entirely appropriate. Historically, the elderly have been under-represented in clinical trials that include study participants 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

APRIL 14, 2021

A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Government 52

Government Long-Term Care Facilities Hospitals Treatment 52

The Pharma Data

APRIL 16, 2021

A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

JANUARY 26, 2021

BLAZE-4 Additionally, initial results from the ongoing BLAZE-4 trial provide viral load and pharmacodynamic/pharmacokinetic data which demonstrated lower doses, including bamlanivimab 700 mg and etesevimab 1400 mg together, are similar to bamlanivimab 2800 mg and etesevimab 2800 mg together.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

MARCH 5, 2021

A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

MARCH 11, 2021

A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

MAY 4, 2021

A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52